CD274 and B-cell chronic lymphocytic leukemia: Previous studies have shown that SLAMF5 facilitates interactions between chronic lymphocytic leukemia (CLL) cells and their microenvironment, promoting CLL cell survival and suppressing T cell activity through upregulation of PD-L1 [33–35].